Home 5 Laboratory Industry Report 5 FDA-lir 5 FDA Watch: Greenlights for NGS Tumor Panels May Augur New Approach to LDT Approvals—Both Product & Pathway

FDA Watch: Greenlights for NGS Tumor Panels May Augur New Approach to LDT Approvals—Both Product & Pathway

by | Jan 16, 2018

From - Laboratory Industry Report A pair of tumor tests highlights the list of new FDA approvals from mid-November through December, including… . . . read more

A pair of tumor tests highlights the list of new FDA approvals from mid-November through December, including:

  • FoundationOne’s CDx (F1CDx) companion diagnostic test for solid tumors; and
  • Memorial Sloan Kettering Cancer Center’s Integrated Mutation Profiling of Actionable Cancer Targets tumor profiling test assay (MSK-IMPACT).

Of course, FDA approval of next-generation sequencing-based (NGS) personalized medicine cancer assays is always a pretty big deal for the diagnostics community. But these developments may have an even deeper significance to the extent they offer clues on the agency’s wider approach to approval of laboratory-developed tests (LDTs) going forward.

The Approved Products
MSK-IMPACT is a 468-gene panel detecting genetic mutations in rare and common cancers. Data Profile: According to the agency, the data demonstrated that the assay is highly accurate (over 99%) and capable of detecting a mutation at a range of 2% to 5%. percent to 5 percent). Additionally, the test could detect microsatellite instabilities 92% of the time across multiple cancer types in 175 cases, when compared to traditional detection methods.

F1CDx can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. Data Profile: The FDA found that the data demonstrated the test’s ability to detect select mutation types with 94.6% accuracy. Of course, this isn’t the first companion diagnostic the agency has approved. However, rather than match one test to one drug the way all previously approved tests do, F1CDx enables matching of patients with five different tumor types to 15 different approved, targeted treatments, including those for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, or ovarian cancer.

The Approval Pathways
The story is not just that both tests were approved but also how they were approved.

MSK-IMPACT became the first comprehensive tumor-profiling LDT to receive FDA authorization through the de novo premarket review pathway. It had previously been approved by the New York State Department of Health as a laboratory-developed clinical test. The FDA authorized MSK-IMPACT as a Class II, moderate-risk device, which enables subsequent, similar types of tests to use the FDA’s less onerous 510(k) clearance pathway.

F1CDx, meanwhile, was approved by the FDA in concert with the CMS under the Parallel Review Program designed to speed up adoption of innovative technologies by allowing for tests to receive FDA approval and immediate Medicare coverage determination simultaneously. The Parallel Review Program is open to certain premarket approval applications for new device technologies that fall within Medicare’s Part A or Part B benefit categories. A final coverage decision is expected in the first quarter of 2018, at which time F1CDx will be made commercially available. Analysts say that simultaneous FDA approval and Medicare coverage could also have a positive impact on private reimbursement decisions.

Other New FDA Approvals
Meanwhile, here’s a rundown of the other key new approvals issued by the FDA in mid-November through December:

NEW FDA APPROVALS

Manufacturer(s)Product(s)
Foundation MedicineApproval of FoundationOne CDx (F1CDx), NGS-based genomic profiling test
Memorial Sloan Kettering Cancer CenterApproval of MSK-IMPACT NGS tumor profiling assay
QuidelApproval of assay to detect Group B Strep using firm’s Solana molecular system
QuidelApproval and CLIA waiver for assay to detect Group A Strep on firm’s Sofia 2 fluorescent immunoassay analyzer
Beckman Coulter DiagnosticsApproval of automated Access AMH test for quantitative determination of anti-Müllerian hormone levels
Ortho Clinical DiagnosticsApproval of Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator for use on Vitros 3600 Immunodiagnostic System
MicrogenicsApproval of CEDIA Heroin Metabolite Assay for detecting presence of heroin metabolite in urine
Siemens HealthineersApproval of:

  • N Latex FLC kappa assay
  • N latex FLC lambda assay
  • N FLC standard SL
  • N FLC Control SL1 and SL2
DxNAApproval of GeneSTAT.MDx Coccidioides test for valley fever
Lia DiagnosticsApproval of Lia Pregnancy Test, making it the first FDA-cleared, flushable, biodegradable pregnancy test, according to the company
HologicApproval of Panther Fusion AdV/hMPV/RV respiratory assay for running on firm’s Panther Fusion system
Sysmex AmericaApproval and CLIA waiver for XW-100 Automated Hematology Analyzer, a complete blood cell count test, for use in health care settings such as doctors’ offices and clinics
GenePOCApproval of GenePOC CDiff test detecting the toxin B gene of toxigenic C. diff strains directly from stool samples
GrifolsApproval of blood-based alpha-1 antitrypsin (AAT) deficiency test

In December, the FDA granted CLIA waivers to the following test kits:

NEW FDA CLIA WAIVERS

Manufacturer(s)Product(s)
AlereAlere, BinaxNOW Influenza A & B Card 2 {With Reader} (Direct Nasal and NP Swabs)
QuidelQuidel Sofia 2 (Sofia RSV FIA)
QuidelQuidel Sofia 2 (Sofia Influenza A+B FIA)
Sysmex AmericaXW-100 Automated Hematology Analyzer

New CE Marks & Global Certifications
Notable European CE certifications:

NEW CE CERTIFICATIONS

Manufacturer(s)Product(s)
EpigenomicsApproval of Epi proLung blood-based lung cancer test
BGIApproval of NIFTY cell-free DNA-based noninvasive prenatal test kit for fetal chromosomal aneuploidies on BGISEQ-500 platform
Bio-Rad LaboratoriesApproval of QXDx BCR-ABL %IS Kit to detect BCR-ABL gene fusions
Vela DiagnosticsApproval of Sentosa SX Cell-free DNA Kit is now CE marked for running on Sentosa SX101 instrument
BiocartisApproval of two liquid biopsy tests to detect RAS mutations in circulating tumor DNA from patients with metastatic colorectal cancer:

  • Idylla ctNRAS-BRAF Mutation Test
  • Idylla ctKRAS Mutation Test

Other key international clearances included World Health Organization approval of Atomo Diagnostics’ Atomo HIV Self Test, an HIV self-test that is now eligible for procurement by organizations that can access Global Fund and Unitaid resources.

This content is exclusive to Laboratory Industry Report subscribers

Start a Free Trial for immediate access to this article and our entire archive of over 20 years of LIR reports.

This content is exclusive to Laboratory Industry Report subscribers

Start a Free Trial for immediate access to this article and our entire archive of over 20 years of LIR reports.